Blauvelt A, Lebwohl MG, Mabuchi T, et al. - Researchers conducted the study for analyzing the safety and effectiveness of the approved ixekizumab (IXE) dose over 5 years from UNCOVER-3. For this randomized controlled trial 1,346 patients were randomized 1:2:2:2 to obtain subcutaneous injections of placebo, etanercept 50 mg twice weekly, IXE 80 mg every 2 weeks (Q2W) or every 4 weeks (Q4W) following an initial dose of IXE 160 mg. In patients using the approved dose, IXE shows sustained effectiveness and consistent safety through 264 weeks. The most observed treatment-emergent adverse events were infections.